Cargando…
2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents
BACKGROUND: Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis (Mtb). The incidence of TB patients is increasing globally and the wide spread of multi- and extensively drug-resistant TB poses a significant burden to patients. This situation calls for an urgent medical need...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677219/ http://dx.doi.org/10.1093/ofid/ofad500.2143 |
_version_ | 1785150078367825920 |
---|---|
author | Son, Young-Jin Hwang, Hee-Jong Shyaka, Clovis Kim, Dahyun Lee, Jusuk Eum, Seokyong Lee, Sun-Kyung |
author_facet | Son, Young-Jin Hwang, Hee-Jong Shyaka, Clovis Kim, Dahyun Lee, Jusuk Eum, Seokyong Lee, Sun-Kyung |
author_sort | Son, Young-Jin |
collection | PubMed |
description | BACKGROUND: Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis (Mtb). The incidence of TB patients is increasing globally and the wide spread of multi- and extensively drug-resistant TB poses a significant burden to patients. This situation calls for an urgent medical need to develop new anti-TB drugs. Through our proprietary medicinal chemistry platform on D-series 26-membered thiopeptide, we have identified a few lead compounds, such as AJ-099 and AJ-206 that exert potent activity against multi-drug resistant TB strains. METHODS: In vitro minimal inhibitory concentration (MIC) was measured and a Mtb-infected human macrophage model was used to evaluate anti-mycobacterial activity of our compounds in drug-sensitive or multidrug-resistant TB isolates. Cellular toxicity and some in vitro ADME tests were also performed and examined. RESULTS: We found that our lead compounds exert potent anti-TB activity on H37Rv(MIC: 0.125-0.5 μg/mL) and showed similar MIC levels in multidrug-resistant clinical isolates. In the macrophage infection model, AJ-099 and AJ-206 showed comparable antimycobacterial effects to isoniazid. These compounds showed no cytotoxicity, relatively safe ADME properties, and no hERG inhibition. In vitro antibacterial activity in multi-drug resistant M. tuberculosis strains [Figure: see text] Antibacterial activity in macrophage infection model [Figure: see text] In vitro ADMET properties of lead compounds [Figure: see text] CONCLUSION: AJ-099 and AJ-206 may be potential anti-TB therapeutic agents that possess novel modes of action, low cardiac and cellular toxicities. DISCLOSURES: Young-Jin Son, A&J Science: Employee of A&J Science|A&J Science: Ownership Interest|KHIDI: Grant/Research Support Hee-Jong Hwang, PhD, A&J Science: Stocks/Bonds|KHIDI: Grant/Research Support Clovis Shyaka, n/a, A&J Science: Employee of A&J Science Dahyun Kim, n/a, A&J Science: Employee of A&J Science Jusuk Lee, Ph.D., A&J Science: Employee of A&J Science |
format | Online Article Text |
id | pubmed-10677219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106772192023-11-27 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents Son, Young-Jin Hwang, Hee-Jong Shyaka, Clovis Kim, Dahyun Lee, Jusuk Eum, Seokyong Lee, Sun-Kyung Open Forum Infect Dis Abstract BACKGROUND: Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis (Mtb). The incidence of TB patients is increasing globally and the wide spread of multi- and extensively drug-resistant TB poses a significant burden to patients. This situation calls for an urgent medical need to develop new anti-TB drugs. Through our proprietary medicinal chemistry platform on D-series 26-membered thiopeptide, we have identified a few lead compounds, such as AJ-099 and AJ-206 that exert potent activity against multi-drug resistant TB strains. METHODS: In vitro minimal inhibitory concentration (MIC) was measured and a Mtb-infected human macrophage model was used to evaluate anti-mycobacterial activity of our compounds in drug-sensitive or multidrug-resistant TB isolates. Cellular toxicity and some in vitro ADME tests were also performed and examined. RESULTS: We found that our lead compounds exert potent anti-TB activity on H37Rv(MIC: 0.125-0.5 μg/mL) and showed similar MIC levels in multidrug-resistant clinical isolates. In the macrophage infection model, AJ-099 and AJ-206 showed comparable antimycobacterial effects to isoniazid. These compounds showed no cytotoxicity, relatively safe ADME properties, and no hERG inhibition. In vitro antibacterial activity in multi-drug resistant M. tuberculosis strains [Figure: see text] Antibacterial activity in macrophage infection model [Figure: see text] In vitro ADMET properties of lead compounds [Figure: see text] CONCLUSION: AJ-099 and AJ-206 may be potential anti-TB therapeutic agents that possess novel modes of action, low cardiac and cellular toxicities. DISCLOSURES: Young-Jin Son, A&J Science: Employee of A&J Science|A&J Science: Ownership Interest|KHIDI: Grant/Research Support Hee-Jong Hwang, PhD, A&J Science: Stocks/Bonds|KHIDI: Grant/Research Support Clovis Shyaka, n/a, A&J Science: Employee of A&J Science Dahyun Kim, n/a, A&J Science: Employee of A&J Science Jusuk Lee, Ph.D., A&J Science: Employee of A&J Science Oxford University Press 2023-11-27 /pmc/articles/PMC10677219/ http://dx.doi.org/10.1093/ofid/ofad500.2143 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Son, Young-Jin Hwang, Hee-Jong Shyaka, Clovis Kim, Dahyun Lee, Jusuk Eum, Seokyong Lee, Sun-Kyung 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
title | 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
title_full | 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
title_fullStr | 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
title_full_unstemmed | 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
title_short | 2525. Identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
title_sort | 2525. identification of lead compounds, belonging to 26-membered thiopeptide antibiotics for new anti-tuberculosis therapeutic agents |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677219/ http://dx.doi.org/10.1093/ofid/ofad500.2143 |
work_keys_str_mv | AT sonyoungjin 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents AT hwangheejong 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents AT shyakaclovis 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents AT kimdahyun 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents AT leejusuk 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents AT eumseokyong 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents AT leesunkyung 2525identificationofleadcompoundsbelongingto26memberedthiopeptideantibioticsfornewantituberculosistherapeuticagents |